Preferred Name |
Dulaglutide |
|
Synonyms |
|
|
Definitions |
A glucagon-like peptide-1 (GLP-1) receptor agonist that is 90% homologous to native human GLP-1 (7-37) and is composed of a dipeptidyl peptidase-IV-protected GLP-1 analog covalently linked to a human immunoglobulin G4 (IgG4)-Fc heavy chain, with antihyperglycemic activity. Upon administration, dulaglutide binds to and activates GLP-1 receptors, thereby increasing intracellular cyclic AMP (cAMP) in pancreatic beta cells. This increases glucose-dependent insulin release. Dulaglutide also reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying. Altogether this lowers the postprandial glucose level. GLP-1 is normally secreted by L cells of the gastrointestinal (GI) mucosa in response to a meal to normalize blood glucose levels. |
|
ID |
http://purl.obolibrary.org/obo/NCIT_C169923 |
|
CAS_Registry |
923950-08-7 |
|
code |
C169923 |
|
Contributing_Source |
FDA |
|
definition |
A glucagon-like peptide-1 (GLP-1) receptor agonist that is 90% homologous to native human GLP-1 (7-37) and is composed of a dipeptidyl peptidase-IV-protected GLP-1 analog covalently linked to a human immunoglobulin G4 (IgG4)-Fc heavy chain, with antihyperglycemic activity. Upon administration, dulaglutide binds to and activates GLP-1 receptors, thereby increasing intracellular cyclic AMP (cAMP) in pancreatic beta cells. This increases glucose-dependent insulin release. Dulaglutide also reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying. Altogether this lowers the postprandial glucose level. GLP-1 is normally secreted by L cells of the gastrointestinal (GI) mucosa in response to a meal to normalize blood glucose levels. |
|
FDA_UNII_Code |
WTT295HSY5 |
|
in_subset | ||
label |
Dulaglutide |
|
NCI_META_CUI |
CL1382408 |
|
Preferred_Name |
Dulaglutide |
|
prefixIRI |
NCIT:C169923 |
|
prefLabel |
Dulaglutide |
|
Semantic_Type |
Pharmacologic Substance |
|
subClassOf |